Aftovaxpur DOE

Country: European Union

Language: Estonian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Maksimaalne kolme järgmistest puhastatud inaktiveeritud suu-ja sõrataudi viiruse tüved: O1 Manisa ≥ 6 PD50*; O1-BFS ≥ 6 PD50*; O Taiwan 3/97 ≥ 6 PD50*; A22 Iraagi ≥ 6 PD50*; A24 Cruzeiro ≥ 6 PD50*; Türgi 14/98 ≥ 6 PD50*; Asia 1 Shamir ≥ 6 PD50*; SAT2 Saudi Araabia ≥ 6 PD50*; * PD50 – 50% kaitsvat doosi kohta veiste, nagu on kirjeldatud Fr. Eur. monograafia 0063.

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QI02AA04

INN (International Name):

inactivated vaccine against foot-and-mouth disease

Therapeutic group:

Pigs; Cattle; Sheep

Therapeutic area:

Immunoloogilised vahendid

Therapeutic indications:

Veiste, lammaste ja sigade aktiivne immuniseerimine alates kahe nädala vanusest suu-ja sõrataudist kliiniliste tunnuste vähendamiseks.

Product summary:

Revision: 8

Authorization status:

Endassetõmbunud

Authorization date:

2013-07-15

Patient Information leaflet

                                17
B. PAKENDI INFOLEHT
Ravimil on müügiluba lõppenud
18
PAKENDI INFOLEHT
AFTOVAXPUR DOE SÜSTEEMULSIOON VEISTELE, LAMMASTELE JA SIGADELE
1.
MÜÜGILOA HOIDJA NING, KUI NEED EI KATTU, RAVIMIPARTII
VABASTAMISE EEST VASTUTAVA TOOTMISLOA HOIDJA NIMI JA AADRESS
Müügiloa hoidja:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
SAKSAMAA
Partii vabastamise eest vastutav tootja:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l’Aviation
69800 Saint Priest
Prantsusmaa
2.
VETERINAARRAVIMI NIMETUS
AFTOVAXPUR DOE süsteemulsioon veistele, lammastele ja sigadele
3.
TOIMEAINETE JA ABIAINETE SISALDUS
Iga 2 ml doos sisaldab:
AKTIIVNE TOIMEAINE:
Puhastatud, inaktiveeritud suu- ja sõrataudi viirustüvede antigeene
vähemalt 6 PD
50
* tüve kohta.
*PD
50
: 50% veiseid kaitsev doos vastavalt Ph.Eur. monograafias 0063
kirjeldatule.
Lõpptootes sisalduv tüvede kogus ja tüüp kohaldatakse sõltuvalt
konkreetsest epidemioloogilisest
olukorrast lõpptoote tootmise ajal ning see näidatakse ära
etiketil.
ADJUVANT:
Vedel parafiin 537 mg
Peale raputamist valge emulsioon.
4.
NÄIDUSTUS(ED)
Veiste, lammaste ja sigade aktiivne immuniseerimine alates 2 nädala
vanusest suu ja –sõrataudi vastu,
et vähendada kliinilisi tunnuseid.
Immuunsuse teke:
Veistel ja lammastel: 7 päeva pärast vaktsineerimist.
Sigadel: 4 nädalat pärast vaktsineerimist.
Immuunsuse kestus: veiste, lammaste ja sigade vaktsineerimine kutsub
esile neutraliseerivate
antikehade tekke, mis püsivad vähemalt 6 kuud. Veistel mõõdetud
antikehade tasemed ületasid
kaitseks vajaliku.
Ravimil on müügiluba lõppenud
19
5.
VASTUNÄIDUSTUSED
Ei ole.
6.
KÕRVALTOIMED
Pärast vaktsiinidoosi manustamist tekkis enamikul loomadest väga
sageli süstekohas paistetus
(mäletsejalistel diameetriga kuni 12 cm ja sigadel kuni 4 cm).
Sellised lokaalsed reaktsioonid
taanduvad tavaliselt iseeneslikult 4 nädala jooksul pärast
vaktsineerimist, kuid vähestel loomadel
võivad püsida kauem.
Sageli täheldati rektaalse temperatuuri kerget t
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
LISA I
RAVIMI OMADUSTE KOKKUVÕTE
Ravimil on müügiluba lõppenud
2
1.
VETERINAARRAVIMI NIMETUS
AFTOVAXPUR DOE süsteemulsioon veistele, lammastele ja sigadele
2.
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS
_ _
Iga 2 ml doosi emulsiooni sisaldab:
TOIMEAINED:
Maksimaalselt kolm järgnevat puhastatud, inaktiveeritud suu- ja
sõrataudi viirustüve:
O1 Manisa
.................................................................................................................................
≥ 6 PD
50
*
O1 BFS
.......................................................................................................................................
≥ 6 PD
50
*
O Taiwan 3/97
...........................................................................................................................
≥ 6 PD
50
*
A22 Iraq
.....................................................................................................................................
≥ 6 PD
50
*
A24 Cruzeiro
.............................................................................................................................
≥ 6 PD
50
*
A Turkey 14/98
.........................................................................................................................
≥ 6 PD
50
*
Asia 1 Shamir
.............................................................................................................................
≥ 6 PD
50
*
SAT2 Saudi
Arabia....................................................................................................................
≥ 6 PD
50
*
*PD
50
: 50% veiseid kaitsev doos vastavalt Ph.Eur. monograafias 0063
kirjeldatule.
Lõpp-tootes esinevate tüvede arv ja tüüp kohaldatakse vastavalt
kehtivale epidemioloogilisele
olukorrale lõpp-toote valmimise ajal ning see on ära toodud
etiketil.
ADJUVANT:
Vedel parafiin
……………………………………………………………………………………537
mg
ABIAINED:
Abiainete täielik loetelu on esitatud lõigus 6.1.
3.
RAVIMVORM
Süsteemulsioon.
P
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-07-2023
Public Assessment Report Public Assessment Report Bulgarian 13-06-2016
Patient Information leaflet Patient Information leaflet Spanish 04-07-2023
Public Assessment Report Public Assessment Report Spanish 04-07-2023
Patient Information leaflet Patient Information leaflet Czech 04-07-2023
Public Assessment Report Public Assessment Report Czech 13-06-2016
Patient Information leaflet Patient Information leaflet Danish 04-07-2023
Public Assessment Report Public Assessment Report Danish 13-06-2016
Patient Information leaflet Patient Information leaflet German 04-07-2023
Public Assessment Report Public Assessment Report German 13-06-2016
Patient Information leaflet Patient Information leaflet Greek 04-07-2023
Public Assessment Report Public Assessment Report Greek 13-06-2016
Patient Information leaflet Patient Information leaflet English 04-07-2023
Public Assessment Report Public Assessment Report English 04-07-2023
Patient Information leaflet Patient Information leaflet French 04-07-2023
Public Assessment Report Public Assessment Report French 04-07-2023
Patient Information leaflet Patient Information leaflet Italian 04-07-2023
Public Assessment Report Public Assessment Report Italian 04-07-2023
Patient Information leaflet Patient Information leaflet Latvian 04-07-2023
Public Assessment Report Public Assessment Report Latvian 04-07-2023
Patient Information leaflet Patient Information leaflet Lithuanian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-07-2023
Public Assessment Report Public Assessment Report Lithuanian 04-07-2023
Patient Information leaflet Patient Information leaflet Hungarian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 04-07-2023
Public Assessment Report Public Assessment Report Hungarian 04-07-2023
Patient Information leaflet Patient Information leaflet Maltese 04-07-2023
Public Assessment Report Public Assessment Report Maltese 04-07-2023
Patient Information leaflet Patient Information leaflet Dutch 04-07-2023
Public Assessment Report Public Assessment Report Dutch 04-07-2023
Patient Information leaflet Patient Information leaflet Polish 04-07-2023
Public Assessment Report Public Assessment Report Polish 04-07-2023
Patient Information leaflet Patient Information leaflet Portuguese 04-07-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 04-07-2023
Public Assessment Report Public Assessment Report Portuguese 04-07-2023
Patient Information leaflet Patient Information leaflet Romanian 04-07-2023
Public Assessment Report Public Assessment Report Romanian 04-07-2023
Patient Information leaflet Patient Information leaflet Slovak 04-07-2023
Public Assessment Report Public Assessment Report Slovak 04-07-2023
Patient Information leaflet Patient Information leaflet Slovenian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 04-07-2023
Public Assessment Report Public Assessment Report Slovenian 04-07-2023
Patient Information leaflet Patient Information leaflet Finnish 04-07-2023
Public Assessment Report Public Assessment Report Finnish 04-07-2023
Patient Information leaflet Patient Information leaflet Swedish 04-07-2023
Public Assessment Report Public Assessment Report Swedish 04-07-2023
Patient Information leaflet Patient Information leaflet Norwegian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 04-07-2023
Patient Information leaflet Patient Information leaflet Icelandic 04-07-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 04-07-2023
Patient Information leaflet Patient Information leaflet Croatian 04-07-2023
Public Assessment Report Public Assessment Report Croatian 04-07-2023

View documents history